Moderna, Inc. (MRNA) Down 6.3% — Is It Worth Holding Any Longer?
Moderna, Inc. (MRNA) is under pressure on Wednesday, changing hands at $190.64, a $12.82 decline from the prior close of $203.46. The pullback comes one day after the stock set its 52-week high of $208.90 on September 29, 2026, and leaves shares about 8.7% below that peak. The broader 52-week range shows how extreme the recent run has been. Even after today's drop, MRNA trades roughly 756% above its 52-week low of $22.28.
Volume stands at approximately 8.53 million shares so far in the session, compared with a 90-day average of roughly 14.23 million. That puts turnover at about 60% of a typical full day with the regular session still open.
Why Moderna, Inc. Price is Moving Lower
The clearest driver is Citi's downgrade of Moderna from Hold to Sell on September 30. Shares were down 6.37% at $190.50 by 10:15 a.m. Eastern after the call. Citi raised its price target from $60 to $80, but that figure still sits about 61% below the previous close of $203.46. Analyst Geoff Meacham argued that the rally has run well ahead of any realistic commercial payoff. His note points out that the shares have climbed 222% since Moderna reported interim results from its INTerpath-001 melanoma trial, while the XBI biotech ETF fell 2% over the same stretch.
The valuation math in Citi's note is what makes the call hard to dismiss. The firm estimated that a share price near $200 would require about $26 billion in annual cancer-drug sales, roughly seven times its own forecast. Citi also said that even if Moderna's lead cancer programs succeed, its analysis supports a value closer to $100 per share. INTerpath-001 met its endpoints, and investors now face a detailed data readout that must justify a valuation Citi believes is already fully priced.
Today's move looks company-specific rather than a sector selloff. XBI was up 0.13% alongside the downgrade coverage. Natera, Inc. (NTRA) gained 1.72% and Revolution Medicines, Inc. (RVMD) rose 1.64%, so the broader group offers no explanation for MRNA's drop. The fundamental backdrop gives little cushion. Moderna's Q2 report on July 31 showed a loss of $1.97 per share, narrower than the $2.03 loss analysts expected and better than the $2.13 loss a year earlier. Revenue of $145 million beat the $102.93 million consensus but grew just 2.1% year over year. That is a thin commercial base to support an $81.23 billion market cap built largely on oncology expectations.
What is the Moderna, Inc. Rating - Should I Sell?
Weiss Ratings assigns MRNA a D- rating. Current recommendation is Sell. That rating has held through the stock's dramatic rally, which suggests the underlying financial profile has not changed nearly as much as the share price. The D- reflects a company whose valuation now rests on pipeline outcomes rather than on results the business currently produces.
The standout strength is the Excellent rating on the Solvency Index. For a company posting a -141.42% profit margin and trailing EPS of -$7.98, balance sheet strength matters. It means Moderna can keep funding late-stage oncology trials and its respiratory franchise without an immediate capital squeeze. That flexibility matters for a pipeline this broad. It does not, however, change the fact that the company is still burning through its resources to get there.
Where the picture becomes more nuanced is in the two indices rated Fair. The Growth Index rating reflects revenue growth of just 2.11% year over year, alongside a steep sequential decline from the first quarter as respiratory vaccine demand swings with the season. Growth has stabilized, but it is not yet expanding. The Fair rating on the Total Return Index may look surprising for a stock that has climbed from $22.28 to above $190 within 52 weeks. The problem is that the gains are concentrated in a compressed window, and today's 6.3% reversal on a single analyst call shows how quickly they can be given back.
The Very Weak rating on the Efficiency Index is the heaviest weight on the overall rating. A forward P/E of -24.71 confirms that losses are expected to continue, and a -141.42% profit margin means Moderna spends well over a dollar for every dollar of revenue it brings in. The Weak Volatility Index fits a stock that has swung from the low $20s to above $200 in under a year and can now drop more than 6% on one downgrade. Within the Health Care sector, Moderna is on par with Natera, Inc. (NTRA, D-) and Revolution Medicines, Inc. (RVMD, D-). It trails Zoetis Inc. (ZTS, D), whose established animal health business gives it a modestly better risk/reward profile in Weiss's framework.
About Moderna, Inc.
Moderna, Inc. (MRNA) is a Health Care company focused on messenger RNA medicines for the United States, Europe, and international markets. Founded in 2010 and headquartered in Cambridge, Massachusetts, the company operated as Moderna Therapeutics, Inc. until it adopted its current name in August 2018. Its commercial business centers on respiratory vaccines. Spikevax and mNEXSPIKE address COVID-19 and mRESVIA targets RSV, while seasonal influenza, combination, and pandemic influenza vaccines extend that franchise.
Beyond respiratory disease, Moderna's pipeline spans latent viruses, with vaccine candidates for cytomegalovirus, Epstein-Barr virus, and HIV. It also covers enteric illness through a norovirus program and public health threats including Zika, Nipah, and Mpox, along with a Lyme disease vaccine on the bacterial side. Oncology has become the centerpiece of investor attention, led by intismeran autogene alongside cancer antigen therapy, T-cell engager, and cell therapy enhancer programs. The rare disease portfolio targets propionic acidemia, methylmalonic acidemia, and cystic fibrosis.
Moderna's main competitive advantage is its mRNA platform, which lets the company move candidates across very different disease areas from a common technological base. The company has built that reach through collaborations with Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, and immatics N.V. It also works with government and nonprofit partners including the Defense Advanced Research Projects Agency, the Biomedical Advanced Research and Development Authority, and The Bill & Melinda Gates Foundation, and it has a technology alliance with OpenAI. That network of partners broadens both its funding sources and its development capacity.
Investor Outlook
Moderna, Inc. (MRNA) carries a Weiss Rating of D- (Sell). Citi's argument that the oncology rally has outrun realistic sales potential makes caution the more defensible stance at current levels. Investors should watch the detailed numerical readout from the INTerpath-001 melanoma trial, any further analyst revisions, and whether upcoming quarterly results show revenue growth moving meaningfully beyond the 2.1% pace of the last quarter. See full rankings of all D- rated Health Care stocks inside the Weiss Stock Screener.
--